Company Active PLC

Company profile

Abingdon Health PLC

UK company 06475379, incorporated on 16 January 2008.

Abingdon Health | Lateral Flow Test Manufacture and Development

Assay development and high-volume lateral flow test contract manufacturing. Helping you move faster, contain risks and embrace opportunities

Company number
06475379
Incorporated
16 Jan 2008
Companies House status
Active

Company identity

Founded / incorporated
16 January 2008

Company number 06475379

Verify at Companies House
Legal name
ABINGDON HEALTH PLC
Company type
Public Limited Company
Region
Yorkshire and the Humber
Registered address
YORK BIOTECH CAMPUS
SAND HUTTON
YORK
ENGLAND
YO41 1LZ
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

Abingdon Health PLC
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

5 events
21 Feb
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

07 Feb
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Jun
2025

Accounts filed

Accounts

Last accounts made up date

16 Jan
2008

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2018
Funded years
2018, 2019
Age at first award
10 years

Projects

2019 Feasibility Studies Lead participant

Dual Capability Time-resolved Fluorescence and Colourimetric Based Lateral Flow Reader for High Sensitivity Diagnostics Applications

1 Jan 2019 to 31 Dec 2020

Awarded
£173,754
Total cost £248,220

"Lateral flow assays (LFA) are diagnostics tests where a liquid sample is applied to a small nitrocellulose membrane pre-patterned with reagents for detection of particular proteins, cells, chemical molecules or microorganisms. The existing market is worth circa $5.5bn per annum (Source: MarketsandMarkets 2017 Lateral Flow Assay Market Report) with LFAs u...

2018 Collaborative R&D Lead participant

Rapid, accurate, on-farm diagnosis and monitoring of mastitis in dairy cows

1 Jun 2018 to 28 Feb 2021

Awarded
£399,410
Total cost £570,586

"As the world population continues to grow, we need to produce more food for more people, without compromising on animal welfare. Disease control in animals plays a major role in achieving this. Disease is estimated to reduce productivity in the livestock industry by 20% per annum, with losses from mortality, treatment costs, increased labour and reduced ...

Product types

Collaborative R&D Feasibility Studies